The future consequences of uncontrollale inflated health costs
Government questions the dollar value of human life
Recently, a depressing story from England provided a glimpse into America's not-too- distant (and oh-so-grim) healthcare future as it could be in the looming Age of Obama. A cancer patient in Britain was denied the drug that could have held his kidney cancer at bay for six months, because treatment was deemed to be too expensive by British healthcare authorities.
And you thought life was a priceless gift from God. Guess again. In Britain, at least, the "priceless gift" has a price tag. And to the British government, Bruce Hardy's life is not worth the $54,000 cost of cancer treatment.
The drug in question is Pfizer's Stutent, which according to clinical trials, can delay the progress of cancer for as much as half a year.
This shocking decision was made by the British government agency called the National Institute for Health and Clinical Excellence (which creates the incredibly ironic acronym of "NICE," even though this particular decision is anything but). According to the guidelines set by this agency, the British government can only "afford" about $22,750 to prolong a person's life – except in rare cases.
Of course, only true apparatchiks could so dispassionately make such an outrageous statement in public, and there's been massive public protests over the ruling throughout the UK – as there should be.